F Riedel1, K Götte, J Schwalb, K Hörmann. 1. Department of Otolaryngology, Head and Neck Surgery, University Hospital of Mannheim, Germany. frank.riedel@hno.ma.uni-heidelberg.de
Abstract
BACKGROUND: Matrix Metalloproteinases (MMPs) have been implicated as playing an important role in cancer invasion and metastasis. MMPs have been identified in a wide variety of malignancies including head and neck squamous cell carcinomas (HNSCC). MATERIAL AND METHODS: We investigated the circulating level of MMP-2 (gelatinase A or 72-kD type IV collagenase) and MMP-9 (gelatinase B or 92-kD type IV collagenase) in sera from patients with various head and neck squamous cell carcinomas (n = 86) as well as from healthy normal controls (n = 47). Serum MMP concentrations were determined as serum immunoreactivity by using a quantitative sandwich enzyme immunoassay technique. For statistical analysis, the t-test and Kruskal-Wallis test were performed. RESULTS: The majority of the patients with HNSCC were found to have high concentrations of serum MMP-9. The levels of MMP-9 in the sera of patients with cancer ranged from 39 to 1547 ng/ml (mean, 417 ng/ml). In contrast, the MMP-9 serum levels in 47 healthy individuals ranged from 30 to 537 ng/ml (mean, 189 ng/ml), MMP-9 serum concentration being significantly higher in HNSCC patients (p = 0.001). MMP-9 serum concentrations of patients with advanced stage HNSCC were significantly higher (p = 0.0449) compared to patients with early stage cancer. No significant difference of MMP-2 serum levels was seen when comparing HNSCC patients and normal controls. CONCLUSION: The present data indicate that the elevation of serum levels of MMP-9, but not MMP-2, may be a useful marker for clinical monitoring of HNSCC patients.
BACKGROUND: Matrix Metalloproteinases (MMPs) have been implicated as playing an important role in cancer invasion and metastasis. MMPs have been identified in a wide variety of malignancies including head and neck squamous cell carcinomas (HNSCC). MATERIAL AND METHODS: We investigated the circulating level of MMP-2 (gelatinase A or 72-kD type IV collagenase) and MMP-9 (gelatinase B or 92-kD type IV collagenase) in sera from patients with various head and neck squamous cell carcinomas (n = 86) as well as from healthy normal controls (n = 47). Serum MMP concentrations were determined as serum immunoreactivity by using a quantitative sandwich enzyme immunoassay technique. For statistical analysis, the t-test and Kruskal-Wallis test were performed. RESULTS: The majority of the patients with HNSCC were found to have high concentrations of serum MMP-9. The levels of MMP-9 in the sera of patients with cancer ranged from 39 to 1547 ng/ml (mean, 417 ng/ml). In contrast, the MMP-9 serum levels in 47 healthy individuals ranged from 30 to 537 ng/ml (mean, 189 ng/ml), MMP-9 serum concentration being significantly higher in HNSCC patients (p = 0.001). MMP-9 serum concentrations of patients with advanced stage HNSCC were significantly higher (p = 0.0449) compared to patients with early stage cancer. No significant difference of MMP-2 serum levels was seen when comparing HNSCC patients and normal controls. CONCLUSION: The present data indicate that the elevation of serum levels of MMP-9, but not MMP-2, may be a useful marker for clinical monitoring of HNSCC patients.
Authors: Ragini D Singh; N Haridas; Jayendra B Patel; Franky D Shah; Shilin N Shukla; Pankaj M Shah; Prabhudas S Patel Journal: Indian J Clin Biochem Date: 2010-08-25
Authors: G Tsiropoulos; T Papadas; Ie Triantaphyllidou; S Naxakis; K Markou; S Triaridis; I Vital; P Goumas; Dh Vynios Journal: Hippokratia Date: 2013-07 Impact factor: 0.471
Authors: N El Houda Agueznay; C Badoual; S Hans; A Gey; B Vingert; S Peyrard; F Quintin-Colonna; P Ravel; P Bruneval; S Roncelin; B Lelongt; J Bertoglio; W H Fridman; D Brasnu; E Tartour Journal: Clin Exp Immunol Date: 2007-08-03 Impact factor: 4.330
Authors: Sa Do Kang; Sreejata Chatterjee; Samina Alam; Anna C Salzberg; Janice Milici; Sjoerd H van der Burg; Craig Meyers Journal: J Virol Date: 2018-09-26 Impact factor: 5.103